ArticleBMC infectious diseases2026
Crimean-congo hemorrhagic fever in Iraq, 2021-2024: epidemiological and clinical data analysis with proposed severity indicators for resource-constrained settings.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCrimean-Congo hemorrhagic fever (CCHF) is a high-fatality zoonotic infection. Iraq has experienced a substantial increase in reported CCHF cases since 2021, yet predictors of mortality and the feasibility of existing severity scores in routine care have not been systematically assessed. We aimed to identify demographic, clinical and laboratory predictors of death among confirmed CCHF patients in Iraq and to develop a simplified severity score suitable for bedside use in resource-constrained settings.
methodsWe analyzed 273 laboratory-confirmed CCHF cases with known outcomes reported to the Iraqi national surveillance system from 1 January 2021 to 31 December 2024 (273/1,193 confirmed cases with complete standardized forms). Demographic, exposure, clinical, and laboratory variables (including platelet count and cycle threshold [Ct] values) were extracted from harmonized Ministry of Health and Central Public Health Laboratory databases. Univariable and multivariable logistic regression were used to identify mortality predictors. Receiver Operating Characteristic (ROC) curve analysis compared the discriminative performance (area under the curve, AUC) of newly proposed scores with existing CCHF Severity Scoring Index (SSI) and Swanepoel's Grading Score (SGS).
resultsThe overall case fatality rate was 12.1% (33/273). Age, sex, occupation, place of residence, and exposure history were not significantly associated with mortality. In univariable analysis, low platelet count (< 20 × 10³/µL), high viral load (Ct ≤ 25), epistaxis, gastrointestinal bleeding, any bleeding, and jaundice were associated with increased odds of death; after false discovery rate correction, epistaxis, gastrointestinal bleeding, any bleeding, and jaundice remained significant. In multivariable analysis, only epistaxis retained an independent association with mortality (adjusted OR 4.70; 95% CI 1.08-20.4). A laboratory-enhanced three-variable score (epistaxis, low platelet count, Ct ≤ 25) achieved an AUC of 0.70, similar to SSI (0.69). A two-variable score (epistaxis + low platelet count) had an AUC of 0.69, and a purely clinical score (epistaxis, any bleeding, jaundice) an AUC of 0.62, close to SGS (0.64).
conclusionEpistaxis and jaundice emerged as pragmatic clinical red-flag indicators of poor outcome, with low platelet count and high viral load supporting risk stratification where available. Very simple, clinically based scores performed comparably to existing complex tools and may facilitate earlier triage and intensified supportive care for high-risk CCHF patients in resource-limited settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.